Chronic News and Research

RSS

Forest Laboratories' Bystolic tablets for treatment of stable CHF failed to receive FDA approval

Forest Laboratories, Inc. announced today that the U.S. Food and Drug Administration did not approve the additional indication for Bystolic® (nebivolol) tablets as a treatment for stable chronic heart failure (CHF) as requested in the company’s Supplemental New Drug Application (sNDA).

23 Feb 2010

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

Salix Pharmaceuticals, Ltd. today reported that the Gastrointestinal Drugs Advisory Committee of the FDA has recommended by a vote of 14 to 4 in favor of the approval of XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy (HE).

23 Feb 2010

Timely treatment and rehabilitation key to proper healing

Sometimes athletes can be their own worst enemy especially when they continue to play following an injury to a foot or ankle. Surgeons presenting at the Annual Scientific Conference of the American College of Foot and Ankle Surgeons (ACFAS) today are discussing athletic injuries and the importance of proper diagnosis, prompt treatment, and full healing and rehabilitation.

23 Feb 2010

Medtronic third-quarter revenues up by 10%

Medtronic, Inc. today reported financial results for the third quarter of fiscal year 2010, which ended January 29, 2010.

23 Feb 2010

Aradigm initiates dosing in Phase 2b trial of inhaled liposomal ciprofloxacin formulations in BE patients

Aradigm Corporation today announced that it dosed the first patient in the U.S. as part of its ORBIT-1 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) trial, an international, randomized, double-blind, placebo-controlled Phase 2b study designed to evaluate the Company's inhaled liposomal ciprofloxacin (ARD-3100) in patients with non-cystic fibrosis bronchiectasis (BE) under a U.S. IND. This orphan disease indication is a chronic, severe respiratory disease and there are currently no approved treatments for this disease in the U.S.

23 Feb 2010

Medco Health Solutions announces record 16.7% increase in total net revenues for 2009

Medco Health Solutions, Inc. today reported record fourth-quarter 2009 GAAP diluted earnings per share of $0.70, up 29.6 percent compared to $0.54 in fourth-quarter 2008. Excluding the amortization of intangible assets that existed when Medco became a publicly traded company in 2003, fourth-quarter 2009 diluted earnings per share increased 28.8 percent to a record $0.76. Medco also reported record full-year 2009 GAAP diluted earnings per share of $2.61, up 22.5 percent -- exceeding the high-end of the company's guidance.

23 Feb 2010

Dental checkup before first baby tooth appears may help a lifetime of preventive dental care

Tooth decay is the single most common chronic childhood disease, according to the U.S. Surgeon General. This February, the American Academy of Pediatric Dentistry (AAPD) encourages parents and caregivers to "Get it Done in Year One." Visiting a pediatric dentist by the time the first baby tooth appears enables the child to begin a lifetime of preventive dental care, helping to minimize tooth decay and cavities. In fact, studies show that dental costs for children who have their first dental visit before age one are 40 percent lower in the first five years than for those who do not see a dentist prior to their first birthday.

23 Feb 2010

Prevention of preterm birth and stillbirth: Global collaborative efforts needed

A new report identifies the enormous global impact of preterm birth and stillbirth—and what can be done to decrease it. Globally, an estimated 13 million babies are born preterm each year. Newborn deaths now account for more than 42 percent of mortality in children under the age of five, a rise from 37 percent in the year 2000. Additionally, an estimated 3.2 million are stillborn each year, and many of these losses are linked to maternal deaths.

23 Feb 2010

NewCardio's CardioBip technology for remote wireless monitoring demonstrates reliable detection of AF

NewCardio, Inc., a cardiac diagnostic technology provider, announced today that the Heart Rhythm Society (HRS) has accepted an abstract detailing the superior performance of NewCardio's patented CardioBip™ technology for remote wireless monitoring and detection of atrial fibrillation (AF). The study results, which discuss the use of CardioBip for improved AF monitoring and detection, are scheduled for oral presentation at the Heart Rhythm Society 31st Annual Scientific Sessions, May 12-15, 2010, in Denver, Colorado.

23 Feb 2010

FDA issues approval for Gileads's Cayston for respiratory symptoms in cystic fibrosis

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Cayston® (aztreonam for inhalation solution) as a treatment to improve respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa. Cayston’s safety and efficacy have not been established in pediatric patients below the age of 7, patients with forced expiratory volume in one second of less than 25 percent or greater than 75 percent predicted, or patients colonized with Burkholderia cepacia.

23 Feb 2010

Humans can harbor bacteria in gallstones, infect others with active typhoid fever

A new study suggests that the bacteria that cause typhoid fever collect in tiny but persistent communities on gallstones, making the infection particularly hard to fight in so-called "carriers" - people who have the disease but show no symptoms.

23 Feb 2010

Centric Health Resources and CHT to create sustainable healthcare system for Americans

St. Louis-based Centric Health Resources, Inc. joined the Center for Health Transformation (CHT) a high-impact collaboration of private and public sector leaders committed to creating a 21st Century Intelligent Health System that saves lives and money for all Americans.

23 Feb 2010

Aetna selects Millennium Laboratories as national pain management services provider

Millennium Laboratories, a leading provider of therapeutic drug monitoring and education to physicians and staff treating chronic pain patients, announced today a national agreement with Aetna, one of the nation’s leading diversified health care benefits companies that serves approximately 36.3 million people. Under the terms of the three-year ancillary services agreement which went into effect February 1, 2010, Millennium Laboratories’ will assist Aetna participating physicians nationwide with state-of-the-art therapeutic drug monitoring services and tools.

23 Feb 2010

Role of behavioral health in pediatric IBD: NIHCD awards $500,000 grant to further study

The National Institutes of Health has awarded a two-year development grant to researchers with Hasbro Children's Hospital and the Bradley Hasbro Children's Research Center to better understand the role behavioral health plays in pediatric inflammatory bowel disease (IBD), a condition that causes chronic and painful inflammation in the gastrointestinal tract.

23 Feb 2010

BCBSA’s statement on Obama's healthcare reform proposal

President Obama's proposal to establish a new Health Insurance Rate Authority ignores the unique cost drivers in each of the 50 state insurance markets. Several governors from both parties have recently expressed reservations about a one-size-fits-all approach to healthcare reform.

23 Feb 2010

Boehringer Ingelheim Pharmaceuticals receives FDA approval for Mirapex ER in treatment of early PD

Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Mirapex ER® (pramipexole dihydrochloride) extended-release tablets, a new once-daily treatment option for the signs and symptoms of early idiopathic Parkinson's disease (PD). MIRAPEX ER is not indicated in advanced PD. Parkinson's disease is a chronic, slowly progressive and potentially debilitating neurological condition affecting nearly one million people in the U.S., with one person newly diagnosed every nine minutes.

22 Feb 2010

Alnylam Pharmaceuticals initiates ALN-RSV01 Phase IIb trial in adult lung transplant patients for RSV infection

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated a Phase IIb trial in adult lung transplant patients with ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection. RSV infection in lung transplant patients represents an important unmet medical need; the condition is associated with significant morbidity, including the development of acute lung transplant rejection in 10% to 20% of infected patients.

22 Feb 2010

New gene locus influencing risk for atrial fibrillation identified

Atrial fibrillation is a cardiac arrhythmia - a chronic irregularity of heartbeat - which affects an estimated 1 million people in Germany. Although the condition is not acutely life-threatening, it does increase the risk of developing more serious illnesses, such as cardiac insufficiency, stroke and dementia. In the third of a series of genomewide asssociation studies, an international team of researchers, led by LMU physician PD Dr. Stefan K--b, now reports the identification of a new gene locus that has a significant influence on risk for atrial fibrillation.

22 Feb 2010

Roots of many adult diseases sprout in poverty: Scientist to discuss at AAAS meeting

The roots of many adult diseases sprout in poverty and other burdens on the socially disadvantaged. Rockefeller University-s Bruce S. McEwen, a self-described molecular sociologist, will talk about the effects such environmental stressors have on the brain and in turn other organ systems in a talk in San Diego this Friday at the 2010 meeting of the American Association for the Advancement of Science

22 Feb 2010

Scientists develop new mathematical model to understand CML better

Doctors can now understand better chronic myeloid leukaemia (CML), including how it responds to therapy, thanks to a new mathematical model for the disease, developed by scientists in Portugal, Belgium and the United States. The work, to be published in the June edition of the journal Haematologica, also reveals that current therapies - which are not believed to cure CML - with the right protocol can actually get rid of the disease, and provides guidelines on how to do that.

21 Feb 2010

Chronic News and Research

Forest Laboratories' Bystolic tablets for treatment of stable CHF failed to receive FDA approval

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

Timely treatment and rehabilitation key to proper healing

Medtronic third-quarter revenues up by 10%

Aradigm initiates dosing in Phase 2b trial of inhaled liposomal ciprofloxacin formulations in BE patients

Medco Health Solutions announces record 16.7% increase in total net revenues for 2009

Dental checkup before first baby tooth appears may help a lifetime of preventive dental care

Prevention of preterm birth and stillbirth: Global collaborative efforts needed

NewCardio's CardioBip technology for remote wireless monitoring demonstrates reliable detection of AF

FDA issues approval for Gileads's Cayston for respiratory symptoms in cystic fibrosis

Humans can harbor bacteria in gallstones, infect others with active typhoid fever

Centric Health Resources and CHT to create sustainable healthcare system for Americans

Aetna selects Millennium Laboratories as national pain management services provider

Role of behavioral health in pediatric IBD: NIHCD awards $500,000 grant to further study

BCBSA’s statement on Obama's healthcare reform proposal

Boehringer Ingelheim Pharmaceuticals receives FDA approval for Mirapex ER in treatment of early PD

Alnylam Pharmaceuticals initiates ALN-RSV01 Phase IIb trial in adult lung transplant patients for RSV infection

New gene locus influencing risk for atrial fibrillation identified

Roots of many adult diseases sprout in poverty: Scientist to discuss at AAAS meeting

Scientists develop new mathematical model to understand CML better

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News